First Trust Nasdaq Pharmaceuticals ETF Rating $27.64 -0.65 (-2.30%) As of 03:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock First Trust Nasdaq Pharmaceuticals ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FTXH Aggregate RatingModerate Buy 2.63Holdings in FTXH have an aggregate rating of Moderate Buy based on 762 analyst ratings issued in the past year covering 50 companies (99.9% of the portfolio).FTXH Aggregate Price Target$27.64High Prediction$27.64Average Prediction$27.64Low Prediction$27.64Holdings in FTXH have an aggregate price target of $27.64 and a range of $27.64 to $27.64 covering 50 companies (99.9% of the portfolio).FTXH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy12 Buy rating(s)Moderate Buy26 Moderate Buy rating(s)Hold10 Hold rating(s)Reduce2 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by First Trust Nasdaq Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 FTXH Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings9.05%BMYBristol-Myers Squibb$59.22-3.0%3.8057 of 5 stars2.32$57.86 -2.3%19Positive News8.13%ABBVAbbVie$201.12-3.8%4.7466 of 5 stars2.92$211.45 5.1%25Positive News7.39%JNJJohnson & Johnson$161.14-1.3%4.5141 of 5 stars2.56$171.33 6.3%18Positive News6.80%PFEPfizer$25.56-2.2%4.9144 of 5 stars2.63$31.92 24.9%16Analyst RevisionPositive News5.97%MRKMerck & Co., Inc.$87.88-4.8%5 of 5 stars2.65$117.12 33.3%23High Trading Volume5.12%GILDGilead Sciences$107.89+1.1%4.4849 of 5 stars2.72$104.52 -3.1%29Positive News4.41%CAHCardinal Health$132.86-0.3%4.4895 of 5 stars2.71$139.36 4.9%14Positive News3.91%JAZZJazz Pharmaceuticals$135.25-4.8%4.9477 of 5 stars2.93$187.71 38.8%14Positive NewsHigh Trading Volume3.56%AMGNAmgen$306.86-2.4%4.1779 of 5 stars2.46$314.04 2.3%24Positive News3.36%ZTSZoetis$161.29-1.2%4.8065 of 5 stars3.08$215.90 33.9%12Positive News3.28%LLYEli Lilly and Company$852.35-1.5%4.6196 of 5 stars2.85$1,009.72 18.5%20Analyst RevisionPositive News3.19%UTHRUnited Therapeutics$316.73-1.0%4.4039 of 5 stars2.67$388.25 22.6%12Insider Trade2.93%VTRSViatris$8.95-3.8%2.0057 of 5 stars1.75$10.50 17.3%42.60%BIIBBiogen$139.16-1.7%4.8475 of 5 stars2.43$213.33 53.3%30News CoveragePositive News2.49%OGNOrganon & Co.$14.74-3.8%4.8578 of 5 stars2.43$20.80 41.1%7Positive News2.16%CRLCharles River Laboratories International$161.57-3.2%4.4637 of 5 stars1.94$189.77 17.5%162.13%REGNRegeneron Pharmaceuticals$634.14-4.1%4.8627 of 5 stars2.76$973.13 53.5%25Positive News1.74%MEDPMedpace$324.51-1.8%4.1484 of 5 stars2.38$376.30 16.0%13Analyst UpgradeNews CoveragePositive News1.41%HALOHalozyme Therapeutics$64.84+1.3%4.2843 of 5 stars2.60$62.78 -3.2%10Positive News1.40%ELANElanco Animal Health$10.51-1.7%4.3752 of 5 stars2.43$15.17 44.3%71.28%ALKSAlkermes$33.88-2.6%4.3261 of 5 stars2.69$38.46 13.5%13Positive News1.24%NBIXNeurocrine Biosciences$116.18+0.5%4.8916 of 5 stars2.83$165.24 42.2%23Positive News1.17%EXELExelixis$37.710.0%4.6681 of 5 stars2.50$37.59 -0.3%20Positive News1.00%PRGOPerrigo$27.25-1.8%4.8665 of 5 stars2.25$33.00 21.1%4Analyst RevisionPositive News0.98%PBHPrestige Consumer Healthcare$85.04-0.4%4.0693 of 5 stars2.50$93.33 9.8%6Positive News0.94%ITCIIntra-Cellular Therapies$131.703.6048 of 5 stars2.47$106.08 -19.5%15Positive News0.94%TGTXTG Therapeutics$42.80+0.4%3.0605 of 5 stars2.83$40.67 -5.0%6Positive News0.93%PTGXProtagonist Therapeutics$51.05-2.8%2.9009 of 5 stars3.00$62.56 22.5%9Positive News0.86%CORTCorcept Therapeutics$58.32-1.9%4.3816 of 5 stars3.00$99.75 71.0%5Analyst Revision0.63%ALNYAlnylam Pharmaceuticals$280.96-3.4%4.5739 of 5 stars2.76$312.30 11.2%25Analyst UpgradeNews Coverage0.62%ADMAADMA Biologics$20.22-0.5%2.2846 of 5 stars3.25$22.50 11.3%4Positive News0.54%VRTXVertex Pharmaceuticals$509.04-0.5%3.8617 of 5 stars2.65$506.70 -0.5%26Positive News0.54%INSMInsmed$78.54-1.1%3.8212 of 5 stars3.00$94.00 19.7%160.54%ACLXArcellx$72.16-0.4%2.2121 of 5 stars3.13$108.46 50.3%150.54%ACADACADIA Pharmaceuticals$17.11-0.7%4.452 of 5 stars2.50$23.93 39.9%160.52%AMRXAmneal Pharmaceuticals$8.53-4.0%3.4702 of 5 stars3.00$10.80 26.6%5Positive News0.51%KRYSKrystal Biotech$192.30-1.1%4.791 of 5 stars3.00$220.00 14.4%8Positive News0.50%TWSTTwist Bioscience$44.25-1.5%2.8493 of 5 stars2.70$54.40 22.9%10News Coverage0.49%BPMCBlueprint Medicines$93.08-2.3%2.9068 of 5 stars2.70$124.95 34.2%230.48%VCELVericel$47.96+0.0%2.731 of 5 stars3.00$62.29 29.9%7News CoveragePositive News0.48%INCYIncyte$62.08-1.1%4.8188 of 5 stars2.21$74.88 20.6%19Analyst Forecast0.47%ROIVRoivant Sciences$10.67-1.5%1.9257 of 5 stars3.00$17.10 60.3%6Insider Trade0.46%BMRNBioMarin Pharmaceutical$71.53-0.6%4.9852 of 5 stars2.71$94.00 31.4%24Analyst Revision0.39%EXASExact Sciences$45.67-3.0%4.4019 of 5 stars2.90$70.83 55.1%20Positive News0.38%RNAAvidity Biosciences$32.10-3.6%1.874 of 5 stars3.00$66.69 107.8%130.36%IONSIonis Pharmaceuticals$32.27-3.5%4.277 of 5 stars2.70$59.44 84.2%20Analyst Forecast0.36%KYMRKymera Therapeutics$31.82-5.6%1.3698 of 5 stars2.87$56.36 77.1%15Positive News0.31%SRPTSarepta Therapeutics$73.61-3.6%4.5729 of 5 stars2.83$167.41 127.4%230.24%VKTXViking Therapeutics$27.98-4.4%4.4816 of 5 stars3.00$97.67 249.1%13Positive News0.18%MYGNMyriad Genetics$9.73-2.5%4.288 of 5 stars2.20$21.89 125.0%15 This page (NASDAQ:FTXH) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust Nasdaq Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust Nasdaq Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FTXH Stock Free FTXH Stock Alerts